LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
30 funds hold it · Insiders net selling
No insider open-market trades in 90 days (SEC Form 4). Congress: net selling of $1K to $64K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 28, 2026
Financial period
Q3 2026
Earnings per share
$1.99 expected
Revenue
$2.63B expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 28, 2026 | $2.62est. $1.99 | +31.53%beat | $2.80Best. $2.63B+6.53% | +10.6%from $2.53B |
| Jun 30, 2026Reported Jul 29, 2026 | $3.60est. $2.03 | +77.38%beat | $2.74BSEC filing | +3.4%from $2.65B |
| Mar 31, 2026Reported Apr 29, 2026 | $3.57est. $2.95 | +20.93%beat | $2.48BSEC filing | +1.9%from $2.43B |
| Dec 31, 2025Reported Feb 6, 2026 | $1.99est. $1.62 | +23.18%beat | $2.28BAlpha Vantage | -7.1%from $2.45B |
| Sep 30, 2025Reported Oct 30, 2025 | $4.81est. $3.88 | +23.97%beat | $2.53BSEC filing | +2.8%from $2.47B |
| Jun 30, 2025Reported Jul 31, 2025 | $5.47est. $3.88 | +40.98%beat | $2.65BSEC filing | +7.3%from $2.46B |
| Mar 31, 2025Reported May 1, 2025 | $3.02est. $2.95 | +2.37%beat | $2.43BSEC filing | +6.1%from $2.29B |
| Dec 31, 2024Reported Feb 12, 2025 | $3.44est. $3.36 | +2.38%beat | $2.45BAlpha Vantage | +2.9%from $2.39B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.28B | $2.48B | $2.74B | $2.80B |
| Cost of what it sold | $496.3M | $661.0M | $1.18B | $748.4M |
| Gross profit | $1.78B | $1.82B | $1.56B | $2.06B |
| What it spent | ||||
| Research and development | $509.3M | $573.0M | $495.6M | $574.0M |
| Sales and admin | $683.0M | $607.3M | $709.7M | $752.0M |
| Other operating costs | $647.7M | $239.1M | $34.0M | $601.3M |
| Total operating expenses | $1.84B | $1.42B | $1.24B | $1.93B |
| What was left | ||||
| Operating profit | -$57.0M | $397.4M | $318.1M | $128.4M |
| Interest on debt | $67.5M | $67.6M | $82.3M | $87.5M |
| Profit before tax | -$211.0M | $377.7M | $132.4M | -$9.0M |
| Tax | -$162.6M | $58.2M | $34.9M | $11.6M |
| Net profit | -$48.4M | $319.5M | $97.5M | -$20.6M |
| EBITDA | $56.7M | $621.5M | $450.8M | $319.6M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Morgan Stanley downgrades Halozyme stock rating on valuation By Investing.com
NeutralNov 11Ultragenyx Pharmaceutical (RARE) Could Be 38% Undervalued After UK UX111 Filing Progress
NeutralNov 11Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update
NeutralNov 10Biogen to Participate in the Jefferies Global Healthcare Conference
NeutralNov 10Fortress Biotech licenses FB-607 for IBS-D treatment from Cedars-Sinai
Leans bullishNov 10Stifel's Paul Matteis: Biogen's lupus readouts, a strange psilocybin filing and biotech's rising political risk
Leans bullishNov 10Form SCHEDULE 13G BIOGEN INC. Filed by: STATE STREET CORP
NeutralNov 10Goldman Sachs initiates City Therapeutics stock at Early-Stage Biotech
NeutralNov 1032 macro signals shaping BIIB right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
